We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biametrics Launches b-screen® Microarray Screening Device

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Biametrics GmbH has announced the launch of its b-screen® label-free microarray screening device in European markets.

The device is an analysis tool for microarrays in the standard microscope format allowing the detailed studies of biomolecular interactions.

Current applications include bioanalytics, drug discovery, production and quality control. Based on the same technology, the company develops b-portable®, a point-of-care device for early cancer and infection detection.

b-screen® is able to handle different sample types like body fluids (e.g. serum or whole blood) and other relevant complex matrices such as cell culture medium.

Kinetic data can be obtained for almost any kind of biomolecular interaction such as for protein/protein, peptide/protein and small molecules/protein.

b-screen® provides a label-free read-out of up to 10,000 spots per square centimeter. It utilizes a precise and automated microfluidics system for incubation of the microarray with the sample of interest.

The device can be used with multiple array layouts (highly scalable), uses glass or plastic type substrates and is compatible with almost any common microarray printer. The high-throughput analysis is characterized by a high time resolution (no scanning) at low noise of the optical readout.

No fluorescence labels are needed, which leads to assay conditions as close as possible to the in-vivo situation combined with minimal sample pre-treatment and minimized reagent consumption.

“With b-screen® users are able to easily transfer existing microarrays directly into a label-free assay format thus gaining additional information on kinetics and thermodynamics at high precision and reliability,” says Günther Proll, Managing Director of Biametrics.

Proll continued, “The device allows very low cost high-throughput screening and the applications we have established demonstrate excellent performance and outcome characteristics. We believe b-screen® provides key advantages over current options like surface plasmon resonance (SPR)”.

Biametrics will present its b-screen® system at Analytica 2014 in Munich, Germany.